Navigation Links
Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

le medications to help control their blood pressure, underscoring the need for effective combination treatments.

High blood pressure affects approximately 74 million, or nearly one in three, US adults. Although high blood pressure can be easily diagnosed and often successfully managed, approximately 36% of US adults treated with antihypertensive medication do not have their blood pressure controlled. If left untreated, high blood pressure can lead to stroke, heart attack, heart failure, kidney failure and vision problems.

Valturna, Tekturna and Diovan are not approved to treat or prevent stroke, heart attack, heart failure, kidney failure or eye problems resulting from high blood pressure.

History of Diovan(R) (valsartan) tablets and Tekturna(R) (aliskiren) tablets

Diovan, which marked its 10th anniversary in 2007, is the number one selling branded high blood pressure medicine worldwide. Diovan's extensive clinical trials program demonstrates the longstanding commitment of Novartis to research.

Tekturna is a direct renin inhibitor in the first new approved class of high blood pressure medicine in more than a decade. Tekturna was approved by the FDA in March 2007 for the treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna in combination with maximal doses of angiotensin-converting enzyme (ACE) inhibitors has not been adequately studied.

The long-term potential of the direct renin inhibitor Tekturna is being evaluated in an extensive clinical program known as ASPIRE HIGHER.

Novartis and Hypertension Management

For decades Novartis has been a leader and innovator in hypertension management, offering a range of innovative therapies designed to help patients with different needs achieve their blood press
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
5. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... WARRINGTON, Pa. , July 29, 2014 /PRNewswire/ ... company dedicated to advancing a new standard of ... financial results on August 5, 2014 before the ... The Company will host a live teleconference ... day. During the conference call, Discovery Labs, management ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, applauds the ... taking a strong position in opposition to current ... 27, 2014 publication.  The New York Times also ... this week exploring the issue called "High Time:  ...
(Date:7/29/2014)... PA & Rockville, MD (PRWEB) July 29, 2014 ... Therapeutics, Inc. (ITI), a vaccine pioneer in the ... financial services firm Newport Coast Securities, Inc. to ... ITI is commercializing LAMP-vax technology, a breakthrough vaccine ... vaccines and immunotherapy market. The company exclusively licensed ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:7/29/2014)... some good news for parents of preterm babies latest ... by the time they become teenagers, the brains of many ... at term. , A study conducted by the University,s ... the preterm child experiences no brain injury in early life, ... good as their term-born peers. , However, the results of ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by ... its cause remains unknown, a new study by a team ... Bonn in Germany and other European institutions confirms for the ... published on 6 July in Nature Genetics , is ... we swallow, a sphincter in the lower esophagus opens, allowing ...
(Date:7/29/2014)... A new study from UC San Francisco is the ... stressors accumulate overtime and accelerate cellular aging, these negative ... exercising and sleeping well. , "The study participants ... telomere shortening than the ones who didn,t maintain healthy ... said lead author Eli Puterman, PhD, assistant professor in ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2
... breathing problems after birth, and rare, inherited DNA differences may ... Medicine in St. Louis. The study is the first ... associated with a significant number of cases of respiratory distress ... RDS is the most common respiratory problem in newborns and ...
... Putnam Valley, NY. (Nov. 27, 2012) A ... Cell Transplantation (21:8), now freely available on-line ... mesenchymal cells derived from skeletal muscle (SM-MSCs) or ... muscle (myocardium) of separate groups of laboratory rats ...
... scientists from the University of Navarra and the Catalan Association ... Maestrazgo caves in Teruel, Spain. Their description has been published ... to one of the most ancient animal species on the ... a region of the Iberian Range where fauna has not ...
Cached Biology News:Gene linked to respiratory distress in babies 2Gene linked to respiratory distress in babies 3Study suggests different organ-derived stem cell injections improve heart function 2Three new arthropod species have been found in the Maestrazgo Caves in Teruel 2
ATGL Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Human sIL-2R/CD25 ELI-PAIR Kit...
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Biology Products: